Clinical Trial Update: A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating atezolizumab as first-line monotherapy for advanced or metastatic non-small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-04-28